{"id":392665,"date":"2025-01-05T14:00:00","date_gmt":"2025-01-05T13:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/?p=392665"},"modified":"2025-01-05T14:44:03","modified_gmt":"2025-01-05T13:44:03","slug":"innovative-therapies-update-2024","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/innovative-therapies-update-2024\/","title":{"rendered":"Innovative therapies &#8211; Update 2024"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>The arsenal of currently researched active substances in the indication area of atopic dermatitis (AD) is considerable. In addition to anti-OX40\/OX40L antibodies, CM310, nemolizumab and neurokinin receptor 1 antagonists, there are also several topical anti-inflammatory therapies, such as tapinarof, ruxolitinib, delgocitinib, roflumilast, difamilast and asivatrep. Some of these innovative therapies have already been approved in some countries.  <\/strong><\/p>\n\n<!--more-->\n\n<p class=\"wp-block-paragraph\">The treatment options for atopic dermatitis (AD) have expanded significantly in recent years, so that a wide range of effective and safe topical and systemic therapies are currently available. The demands and expectations of therapy have increased: the aim is not only to achieve an optimal risk-benefit profile, but also to achieve treatment effects that are as long-lasting as possible. However, the &#8220;unmet needs&#8221; also include certain subgroups of patients who do not respond adequately to the currently available treatment options or do not tolerate them. The convenience factor should not be neglected either; the treatment should be as easy as possible to integrate into the patient&#8217;s everyday life and help to achieve a rapid and lasting improvement in quality of life. With the development of new active ingredients, targets and dosage forms, attempts are being made to close these treatment gaps [1\u20133].      <\/p>\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-full is-resized\"><a href=\"https:\/\/medizinonline.com\/wp-content\/uploads\/2025\/01\/abb1_DP6_s22.png\"><img fetchpriority=\"high\" decoding=\"async\" width=\"1473\" height=\"1224\" src=\"https:\/\/medizinonline.com\/wp-content\/uploads\/2025\/01\/abb1_DP6_s22.png\" alt=\"\" class=\"wp-image-392572\" style=\"width:400px\" srcset=\"https:\/\/medizinonline.com\/wp-content\/uploads\/2025\/01\/abb1_DP6_s22.png 1473w, https:\/\/medizinonline.com\/wp-content\/uploads\/2025\/01\/abb1_DP6_s22-800x665.png 800w, https:\/\/medizinonline.com\/wp-content\/uploads\/2025\/01\/abb1_DP6_s22-1160x964.png 1160w, https:\/\/medizinonline.com\/wp-content\/uploads\/2025\/01\/abb1_DP6_s22-1120x931.png 1120w\" sizes=\"(max-width: 1473px) 100vw, 1473px\" \/><\/a><\/figure>\n<\/div>\n<h3 id=\"new-immunomodulatory-antibody-therapies\" class=\"wp-block-heading\">New immunomodulatory antibody therapies<\/h3>\n\n<p class=\"wp-block-paragraph\">Among the antibody therapies, the OX40\/OX40L axis, IL-31 and the neurokinin-1 receptor on sensory neurons are promising targets in AD [1,2]. In addition, new representatives of established target structures, such as the IL-4 receptor-\u03b1 (IL4R-\u03b1), are being researched.  <\/p>\n\n<p class=\"wp-block-paragraph\"><strong>OX40\/OX40L axis: <\/strong>OX40 is expressed on T cells in lesional AD skin [4]. Binding of the OX40 ligand to OX40 leads to T2-driven immune differentiation, which is targeted by various new drugs [5].   <\/p>\n\n<ul class=\"wp-block-list\">\n<li><em>Rocatinlimab<\/em> (AMG451\/KHK4083) is a subcutaneously administered anti-OX40L antibody that is currently being investigated in Phase III trials in adults with moderate to severe AD. In a Phase IIb study, the dosage of 300 mg every 2 weeks (q2w) proved to be the most effective with an EASI reduction of 61% at week 16 [3]. The most common <em> adverse events (<\/em> AEs), which occurred more frequently than with placebo, were pyrexia (17%), nasopharyngitis (14%) and chills (11%) [6]. Proteomic analyses showed that rocatinlimab reduced Th2\/Th22- and pruritus-associated mediators at week 16, accompanied by a downregulation of Th2, Th1\/17 and Th22-associated genes by week 52.   <\/li>\n\n\n\n<li><em>Other OX-40 inhibitors:<\/em> currently in the pipeline for AD are GBR830 (anti-OX40), telazorlimab (ISB830) and amlitelimab (KY1005; anti-OX40L) [7].  <\/li>\n<\/ul>\n\n<p class=\"wp-block-paragraph\"><strong>IL-4R\u03b1:<\/strong> In addition to the already approved IgG4 antibody dupilumab, which binds to IL-4R\u03b1 and thus inhibits the signaling pathway of IL-4 and IL-13, further active substances are currently in development.  <\/p>\n\n<ul class=\"wp-block-list\">\n<li><em>CBP-201: <\/em>This is an IL-4R\u03b1 inhibitor that is currently being investigated in two Phase II studies (NCT04444752, NCT05017480) and has achieved promising results [8]. A mean change in EASI scores of -63.0% (every 2 weeks, q2w) and -65.4% (every 4 weeks, q4w) was achieved with CBP-201, compared to -40.7% in the placebo group [8].   <\/li>\n\n\n\n<li><em>CM310: <\/em>This anti-IL-4R\u03b1 antibody is currently being investigated in phase II (NCT04805411) and phase III studies (NCT05265923, NCT04893707) [8].  <\/li>\n<\/ul>\n\n<p class=\"wp-block-paragraph\"><strong>IL-31: <\/strong>This cytokine has been shown to be exceedingly significant in itch pathogenesis and serum IL-31 levels correlate with AD severity [9]. IL-31 is involved in the epidermal barrier disruption typical of AD and activates pruriceptive neurons, which release neuropeptides that drive local inflammation in the skin by attracting Th2 cells.   <\/p>\n\n<p class=\"wp-block-paragraph\">The IL-31 receptor \u03b1 chain (IL-31R\u03b1) is an important therapeutic target that is antagonized by nemolizumab [10,11]. In the USA, this biologic is approved for the treatment of prurigo nodularis and in Japan also for AD-associated itching in patients aged \u226513 years [10,12].  <\/p>\n\n<ul class=\"wp-block-list\">\n<li><em>Nemolizumab: <\/em>With nemolizumab 60 mg (q4w) as an add-on to standard topical therapy, 66% achieved a reduction in pruritus and 78% an EASI reduction at week 68 [10]. The most common AEs were nasopharyngitis (33.9%) and AD (25.2%) [11]. Phase III trials of nemolizumab and Phase II trials in children (2-11 years) with moderate to severe AD are currently ongoing.    <\/li>\n<\/ul>\n\n<p class=\"wp-block-paragraph\"><strong>Substance P (SP) and the neurokinin-1 receptor (N\u03ba1R): <\/strong>It is known that these tachykinins are involved in the peripheral and central transmission of histamine-independent itch and that AD patients have elevated SP levels in lesional skin and serum [13,14]. N\u03ba1R are mainly located in the dorsal root ganglion and dorsal horn of the spinal cord.   <\/p>\n\n<ul class=\"wp-block-list\">\n<li>Whether N\u03ba1R antagonists are effective in AD is still not entirely clear, especially since aprepitant with concomitant standard topical therapy did not lead to a significant improvement in pruritus in AD in a placebo comparison. In contrast, serlopitant significantly reduced chronic pruritus in PN [13,15]. Phase III study data on serlopitant and tradipitant with regard to pruritus in AD have not yet been published [14].    <\/li>\n<\/ul>\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-full is-resized\"><a href=\"https:\/\/medizinonline.com\/wp-content\/uploads\/2025\/01\/tab1_DP6_s23.png\"><img decoding=\"async\" width=\"1459\" height=\"1134\" data-src=\"https:\/\/medizinonline.com\/wp-content\/uploads\/2025\/01\/tab1_DP6_s23.png\" alt=\"\" class=\"wp-image-392573 lazyload\" style=\"--smush-placeholder-width: 1459px; --smush-placeholder-aspect-ratio: 1459\/1134;width:400px\" data-srcset=\"https:\/\/medizinonline.com\/wp-content\/uploads\/2025\/01\/tab1_DP6_s23.png 1459w, https:\/\/medizinonline.com\/wp-content\/uploads\/2025\/01\/tab1_DP6_s23-800x622.png 800w, https:\/\/medizinonline.com\/wp-content\/uploads\/2025\/01\/tab1_DP6_s23-1160x902.png 1160w, https:\/\/medizinonline.com\/wp-content\/uploads\/2025\/01\/tab1_DP6_s23-1120x871.png 1120w\" data-sizes=\"(max-width: 1459px) 100vw, 1459px\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" \/><\/a><\/figure>\n<\/div>\n<h3 id=\"new-topical-substances-for-anti-inflammatory-therapy\" class=\"wp-block-heading\">New topical substances for anti-inflammatory therapy  <\/h3>\n\n<p class=\"wp-block-paragraph\">In addition to subcutaneously and orally administered systemic therapeutics, topical anti-inflammatory therapies also play an important role, particularly for AD patients with a limited <em> body surface area (BSA)<\/em> of &lt;10%. Currently at an advanced stage of development are agents that target JAK receptors and TRPV <em>(&#8220;transient receptor potential vanilloid&#8221;) <\/em>, as well as agonists of the aryl hydrocarbon receptor (AhR) [16].   <\/p>\n\n<p class=\"wp-block-paragraph\"><strong>Topical JAK inhibitors:<\/strong> Compared to the systemic application of JAK-i, topical application carries significantly fewer side effect risks.  <\/p>\n\n<ul class=\"wp-block-list\">\n<li><em>Ruxolitinib: <\/em>Ruxolitinib cream inhibits JAK1\/2 and was approved by the US <em> Food and Drug Administration (FDA)<\/em> in 2021 for the treatment of mild to moderate AD in \u226512-year-olds [17]. In the approval-relevant study, good efficacy was also achieved with regard to itching and tolerability also proved to be good. Nasopharyngitis was reported as the most common AE [17].    <\/li>\n\n\n\n<li><em>Delgocitinib: <\/em>This topical JAK-i blocks all JAK molecules and was approved for the treatment of AD in Japan in 2020 [18]. In a phase III study, a four-week treatment with 0.5% delgocitinib cream led to an improvement in local inflammation of around 45%. The most common side effects were folliculitis (2.4%), acne (2.2%) or irritation (1.8%) at the site of application [19].    <\/li>\n\n\n\n<li>Other topical JAK-i are currently being investigated in clinical trials: Brepocitinib (IIb), ATI-1777, Jaktinib and SHR0302 (Phase II\/III) [20].  <\/li>\n<\/ul>\n\n<p class=\"wp-block-paragraph\"><strong>Topical AhR: <\/strong>Aryl hydrocarbon receptors (AhR) are expressed in all skin cells, including keratinocytes and dendritic cells, can be activated by numerous exogenous and endogenous metabolites and mediate epidermal differentiation [22].  <\/p>\n\n<ul class=\"wp-block-list\">\n<li><em>Tapinarof cream 1%: <\/em>This is an AhR agonist that was approved by the FDA in 2022 for the treatment of plaque psoriasis [23]. Tapinarof modulates gene expression by activating AhR signaling pathways, resulting in a downregulation of type 2 inflammation (IL-4, IL-13), normalizing the skin barrier and contributing to a reduction in oxidative stress. In a 12-week, double-blind, randomized Phase II study, adolescent and adult AD patients using 0.5% or 1% tapinarof cream vs. vehicle preparation showed good improvement of eczematous lesions and pruritus [24]. AEs reported were nasopharyngitis, upper respiratory tract infections, worsening of AD and folliculitis [24]. Phase III studies on tapinarof are currently underway [22].      <\/li>\n<\/ul>\n\n<p class=\"wp-block-paragraph\"><strong>Topical phosphodiesterase-4 (PDE4)-i: <\/strong>crisaborole, difamilast and roflumilast inhibit the release of certain cytokines involved in the inflammatory process and have been shown to improve the skin&#8217;s barrier function [25\u201327]. Inhibition of PDE-4 results in an increase in cAMP, which leads to a downregulation of NF\u03baB, an important modulator of cytokine production (e.g. IL-4, IL-5, IL-10). <\/p>\n\n<ul class=\"wp-block-list\">\n<li><em>Crisaborole: <\/em>This topical PDE-4 inhibitor has been approved in the USA and the EU, but was previously only available on the European market to a limited extent.  <\/li>\n\n\n\n<li><em>Roflumilast and difamilast:<\/em> These representatives of the topical PDE-4 inhibitors are currently being researched and may soon be available for the treatment of mild to moderate AD [17,22].  <\/li>\n<\/ul>\n\n<p class=\"wp-block-paragraph\"><strong>Topical TRPV-1 antagonists: <\/strong>TRPV <em>(&#8220;transient receptor potential vanilloid<\/em>&#8220;)-1, i.e. a subfamily of vanilloid receptors, are found on keratinocytes, dendritic cells and sensory neurons and are overexpressed in lesional AD skin. TRPV-1 modulates inflammatory processes as well as histamine-dependent and -independent itching by triggering the release of central neuropeptides such as substance P and CGRP <em>(calcitonin gene-related peptide)<\/em>.   <\/p>\n\n<ul class=\"wp-block-list\">\n<li><em>Asivatrep:<\/em> This selective TRPV-1 antagonist led to improvements in eczematous lesions and pruritus in a randomized vehicle-controlled phase III study in \u226512-year-old patients with mild to moderate AD [21].  <\/li>\n<\/ul>\n\n<p class=\"wp-block-paragraph\">Literature:<\/p>\n\n<ol class=\"wp-block-list\">\n<li>M\u00fcller S, Maintz L, Bieber T: Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs. Allergy 2024; 79(6): 1501\u20131515. <\/li>\n\n\n\n<li>Buhl T, Werfel T: [Atopische Dermatitis &#8211; Perspektiven und unerf\u00fcllte medizinische Bedarfe]. JDDG 2023; 21(4): 349\u2013354.<\/li>\n\n\n\n<li>L\u00e9 AM, Torres T: OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis-Focus on Rocatinlimab and Amlitelimab. Pharmaceutics 2022 Dec 8; 14(12): 2753.  <\/li>\n\n\n\n<li>Nakagawa H, et al.: Safety, tolerability and efficacy of repeated intravenous infusions of KHK4083, a fully human anti-OX40 monoclonal antibody, in Japanese patients with moderate to severe atopic dermatitis. J Dermatol Sci 2020; 99: 82\u201389.<\/li>\n\n\n\n<li>Elsner JS, et al.: The OX40 Axis is associated with both systemic and local involvement in atopic dermatitis. Acta Derm Venereol 2020; 100: adv00099.<\/li>\n\n\n\n<li>Guttman-Yassky E, et al.: An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study. Lancet 2022; 401(10372): 204\u2013214. <\/li>\n\n\n\n<li>Clinicaltrials, <a href=\"https:\/\/clinicaltrials.gov\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/clinicaltrials.gov,<\/a> status 2022. <\/li>\n\n\n\n<li>Facheris P, et al.: The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment. Cell Mol Immunol 2023; 20(5): 448\u2013474. <\/li>\n\n\n\n<li>Datsi A, et al.: Interleukin-31: the \u00abitchy\u00bb cytokine in inflammation and therapy. Allergy 2021; 76: 2982\u20132997.<\/li>\n\n\n\n<li>Kabashima K, et al.: Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68\u2009weeks: results from two phase III, long-term studies. Br J Dermatol 2022; 186: 642\u2013651.<\/li>\n\n\n\n<li>Kabashima K, et al.: Trial of Nemolizumab and topical agents for atopic dermatitis with pruritus. N Engl J Med 2020; 383: 141\u2013150.<\/li>\n\n\n\n<li>Keam SJ: Nemolizumab: First Approval. Drugs. 2022; 82: 1143\u20131150.<\/li>\n\n\n\n<li>St\u00e4nder S, et al.: Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial. JAAD 2019; 80: 1395\u20131402.<\/li>\n\n\n\n<li>Welsh SE, et al.: Neurokinin-1 receptor antagonist tradipitant has mixed effects on itch in atopic dermatitis: results from EPIONE, a randomized clinical trial. JEADV 2021; 35: e338\u2013e340.<\/li>\n\n\n\n<li>Yosipovitch G, et al.: Serlopitant for the treatment of chronic pruritus: results of a randomized, multicenter, placebo-controlled phase 2 clinical trial. JAAD 2018; 78: 882\u2013891.e10.<\/li>\n\n\n\n<li>Bieber T: Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov 2022; 21: 21\u201340.<\/li>\n\n\n\n<li>Kleinman E, et al.: What\u2019s new in topicals for atopic dermatitis. Am J Clin Dermatol 2022; 23: 595\u2013603. <\/li>\n\n\n\n<li>Chovatiya R, Paller AS: JAK inhibitors in the treatment of atopic dermatitis. JACI 2021; 148: 927\u2013940.  <\/li>\n\n\n\n<li>Nakagawa H, et al.: Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study. JAAD 2020; 82(4): 823\u2013831. <\/li>\n\n\n\n<li>Bieber T: Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov 2022; 21: 21\u201340. <\/li>\n\n\n\n<li>Park CW, et al.: Asivatrep, a TRPV1 antagonist, for the topical treatment of atopic dermatitis: phase 3, randomized, vehicle-controlled study (CAPTAIN-AD). JACI 2022; 149: 1340\u20131347.e4.<\/li>\n\n\n\n<li>Freitas E, Gooderham M, Torres T: New topical therapies in development for atopic dermatitis. Drugs 2022; 82: 843\u2013853.  <\/li>\n\n\n\n<li>Keam SJ: Tapinarof cream 1%: first approval. Drugs 2022; 82: 1221\u20131228.<\/li>\n\n\n\n<li>Paller AS, et al.: Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis. JAAD 2021; 84: 632\u2013638.<\/li>\n\n\n\n<li>Zebda R, Paller AS. Phosphodiesterase 4 inhibitors. JAAD 2018; 78(3 Suppl 1): 43\u2013S52,<br\/>doi: 10.1016\/j.jaad.2017.11.056.   <\/li>\n\n\n\n<li>Schlessinger J, et al: Safety, effectiveness, and pharmacokinetics of Crisaborole in infants aged 3 to &lt;24 months with mild-to-moderate atopic dermatitis: A phase IV open-label study (CrisADe CARE 1); Am J Clin Dermatol 2020; 21(2): 275\u2013284. <\/li>\n\n\n\n<li>Saeki H, et al.: Difamilast ointment in adult patients with atopic dermatitis: a phase 3 randomized, double-blind, vehicle-controlled trial. JAAD 2022; 86(3): 607\u2013614, doi: 10.1016\/j.jaad.2021.10.027<\/li>\n\n\n\n<li>Yamamura K, Nakahara T: The Dawn of a New Era in Atopic Dermatitis Treatment. Journal of Clinical Medicine 2022; 11(20): 6145. www.mdpi.com\/2077-0383\/11\/20\/6145, (last accessed 04.12.2024). <\/li>\n<\/ol>\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n<p class=\"has-small-font-size wp-block-paragraph\"><em>DERMATOLOGIE PRAXIS 2024; 34(6): 22\u201324<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The arsenal of currently researched active substances in the indication area of atopic dermatitis (AD) is considerable. In addition to anti-OX40\/OX40L antibodies, CM310, nemolizumab and neurokinin receptor 1 antagonists, there&hellip;<\/p>\n","protected":false},"author":7,"featured_media":392666,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Research highlights in atopic dermatitis  ","footnotes":"","_members_access_role":[],"_members_access_error":""},"category":[11331,11340,11508,11548,11503],"tags":[80610,80616,12624,80612,80615,80614,65697,80609,73237,80613,80611],"powerkit_post_featured":[],"class_list":["post-392665","post","type-post","status-publish","format-standard","has-post-thumbnail","category-allergology-and-clinical-immunology","category-dermatology-and-venereology","category-education","category-rx-en","category-studies","tag-anti-ox40-ox40l-antibodies","tag-asivatrep-en","tag-atopic-dermatitis-en","tag-cm310-en","tag-delgocitinib-en","tag-difamilast-en","tag-nemolizumab-en","tag-neurokinin-receptor-1-antagonists","tag-roflumilast-en","tag-ruxolitinib-en","tag-tapinarof-en","pmpro-has-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-08-24 11:14:38","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":392660,"slug":"therapies-innovantes-mise-a-jour-2024","post_title":"Th\u00e9rapies innovantes - Mise \u00e0 jour 2024","href":"https:\/\/medizinonline.com\/fr\/therapies-innovantes-mise-a-jour-2024\/"},"it_IT":{"locale":"it_IT","id":392652,"slug":"terapie-innovative-aggiornamento-2024","post_title":"Terapie innovative - Aggiornamento 2024","href":"https:\/\/medizinonline.com\/it\/terapie-innovative-aggiornamento-2024\/"},"pt_PT":{"locale":"pt_PT","id":392645,"slug":"terapias-inovadoras-atualizacao-2024","post_title":"Terapias inovadoras - Atualiza\u00e7\u00e3o 2024","href":"https:\/\/medizinonline.com\/pt-pt\/terapias-inovadoras-atualizacao-2024\/"},"es_ES":{"locale":"es_ES","id":392639,"slug":"terapias-innovadoras-actualizacion-2024","post_title":"Terapias innovadoras - Actualizaci\u00f3n 2024","href":"https:\/\/medizinonline.com\/es\/terapias-innovadoras-actualizacion-2024\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/392665","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=392665"}],"version-history":[{"count":2,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/392665\/revisions"}],"predecessor-version":[{"id":393094,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/392665\/revisions\/393094"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/392666"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=392665"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=392665"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=392665"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=392665"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}